Document Detail

Progesterone and progestins: applications in gynecology.
MedLine Citation:
PMID:  11108875     Owner:  NLM     Status:  MEDLINE    
Achievements obtained in infertility treatments over the past two decades have sparked interest in optimizing progesterone administration. Although progesterone is absorbed orally when ingested in micronized form, bioavailability is poor because of extensive liver metabolism. This explains why full predecidual transformation of the endometrium cannot be achieved with oral progesterone and is therefore ineffective for luteal support in in vitro fertilization (IVF). Progesterone administered non-orally can duplicate the endometrial changes normally seen in the menstrual cycle in women whose ovaries are inactive. Similar results have been reported with intramuscular (i.m.) injections and vaginal administration, although tissue levels are higher in the latter case. The recent development of a controlled and sustained release vaginal progesterone gel, Crinone(R) 8%, has made the vaginal route clinically practical by limiting the number of necessary applications to 1 per day. This regimen has been found at least as effective as intramuscular (i.m.) injections in women whose ovaries are inactive (donor egg IVF) and for luteal support in regular IVF. Hence, painful daily i.m. injections of progesterone in oil become unnecessary. The possibility of reducing the number of daily applications of vaginal progesterone to 1 per day, made possible by the sustained release gel Crinone, has opened new possibilities for long-term treatments, as in hormone replacement therapy (HRT). The low incidence of systemic side effects with use of the vaginal progesterone gel used for HRT in amenorrheic women, contrasts with findings related to use of synthetic progestins. Preliminary data suggest that vaginal progesterone can be instrumental in enhancing the notoriously poor long-term compliance of HRT.
D de Ziegler; R Fanchin
Related Documents :
1588295 - Progesterone in diagnosis of ectopic pregnancy.
9685565 - European study on maternal and fetal management of fetal supraventricular tachyarrhythm...
18514805 - Clomiphene citrate modulates the expression of endometrial carbohydrates (especially n-...
21339205 - Pregnancy in primary sclerosing cholangitis.
25022635 - Safety of the newer class of opioid antagonists in pregnancy.
19480325 - Perinatal risk factors affecting the maternal and fetal asymmetric dimethylarginine lev...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Steroids     Volume:  65     ISSN:  0039-128X     ISO Abbreviation:  Steroids     Publication Date:    2000 Oct-Nov
Date Detail:
Created Date:  2000-12-18     Completed Date:  2001-03-29     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0404536     Medline TA:  Steroids     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  671-9     Citation Subset:  IM    
Department of Ob/Gyn, Reproductive Endocrinology, Nyon Medical Center, 1200 Nyon, Switzerlandand Columbia Laboratories, 75008, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Intravaginal
Delayed-Action Preparations
Fertility Agents / pharmacology,  therapeutic use
Genitalia, Female / drug effects
Progesterone / administration & dosage,  pharmacology
Progestins / administration & dosage*,  pharmacology*
Reproductive Techniques
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Fertility Agents; 0/Progestins; 57-83-0/Progesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Endometrial vascular changes and bleeding disturbances with long-acting progestins.
Next Document:  Progestin implants.